Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 10/20 | 0.67 |
| ▸ | HDAC2 | Q92769 | 8/20 | 0.67 |
| ▸ | HDAC6 | Q9UBN7 | 8/20 | 0.67 |
| ▸ | HDAC9 | Q9UKV0 | 7/20 | 0.67 |
| ▸ | HDAC3 | O15379 | 7/20 | 0.67 |
| ▸ | HDAC10 | Q969S8 | 6/20 | 0.67 |
| ▸ | HDAC8 | Q9BY41 | 6/20 | 0.67 |
| ▸ | HDAC4 | P56524 | 5/20 | 0.67 |
| ▸ | HDAC7 | Q8WUI4 | 5/20 | 0.67 |
| ▸ | HDAC11 | Q96DB2 | 5/20 | 0.67 |
| ▸ | HDAC5 | Q9UQL6 | 5/20 | 0.67 |
| ▸ | PARP1 | P09874 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 2/20 | 0.55 |
| ▸ | ELOVL1 | Q9BW60 | 1/20 | 0.54 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
| ▸ | CASP3 | P42574 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24359496 | 1.00 | HDAC1 (0.67) | HDAC1HDAC2HDAC6HDAC9HDAC3 | |
| SCHEMBL24359498 | 1.00 | HDAC1 (0.67) | HDAC1HDAC2HDAC6HDAC9HDAC3 | |
| SCHEMBL24359367 | 0.99 | HDAC1 (0.65) | HDAC1HDAC2HDAC6HDAC9HDAC3 | |
| SCHEMBL24359497 | 0.97 | HDAC1 (0.65) | HDAC1HDAC2HDAC6HDAC9HDAC3 | |
| SCHEMBL29516051 | 0.87 | ALDH1A1 (0.66) | HDAC1HDAC2HDAC6HDAC9HDAC3 | |
| SCHEMBL24359376 | 0.87 | ALDH1A1 (0.66) | HDAC1HDAC2HDAC6HDAC9HDAC3 | |
| SCHEMBL29516267 | 0.86 | HDAC1 (0.62) | HDAC1HDAC2HDAC6HDAC9HDAC3 | |
| SCHEMBL24359499 | 0.86 | HDAC1 (0.74) | HDAC1HDAC2HDAC6HDAC9HDAC3 | |
| SCHEMBL24359383 | 0.85 | HDAC1 (0.70) | HDAC1HDAC2HDAC6HDAC9HDAC3 | |
| SCHEMBL24359606 | 0.85 | HDAC1 (0.76) | HDAC1HDAC2HDAC6HDAC9HDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260125650-A1 | METHODS AND COMPOSITIONS FOR GENERATING HEPATOCYTES | TRAILHEAD BIOSYSTEMS INC (US) | 2026-05-07 | — | — | US | claimed |
| US-12496357-B2 | Compositions and methods for treating sickle cell disease | YALE UNIVERSITY (US) | 2025-12-16 | — | — | US | claimed |
| CN-116705193-A | Screening method of repositioning candidate medicine and application thereof | 长沙金域医学检验实验室有限公司 | 2023-09-05 | — | — | CN | claimed |
| CN-116440129-A | New application of histone deacetylase inhibitor | 南通大学 | 2023-07-18 | — | — | CN | claimed |
| EP-3071040-B2 | METHOD FOR SCALABLE SKELETAL MUSCLE LINEAGE SPECIFICATION AND CULTIVATION | UNIV MISSOURI (US) | 2022-12-28 | — | — | EP | claimed |
| US-20220280656-A1 | COMPOSITIONS AND METHODS FOR TREATING SICKLE CELL DISEASE | YALE UNIVERSITY | 2022-09-08 | — | — | US | claimed |
| US-20260125650-A1 | METHODS AND COMPOSITIONS FOR GENERATING HEPATOCYTES | TRAILHEAD BIOSYSTEMS INC (US) | 2026-05-07 | — | — | US | disclosed |
| EP-4719447-A2 | METHOD TO GENERATE INDUCED RETINAL PROGENITOR CELLS AND TREATMENT USING SUCH CELLS | Academia Sinica (TW) | 2026-04-08 | — | — | EP | disclosed |
| US-12553028-B2 | Method to generate induced oligodendrocyte-lineage cells and treatment using such cells | ACADEMIA SINICA (TW) | 2026-02-17 | — | — | US | disclosed |
| US-12496357-B2 | Compositions and methods for treating sickle cell disease | YALE UNIVERSITY (US) | 2025-12-16 | — | — | US | disclosed |
| EP-3151920-B1 | USE OF INHIBITOR OF APOPTOSIS PROTEIN (IAP) ANTAGONISTS IN HIV THERAPY | SANFORD BURNHAM MED RES INST (US) | 2025-08-06 | — | — | EP | disclosed |
| US-12324817-B2 | Method of inducing dedifferentiation of somatic cells with small molecules to prepare rejuvenated mesenchymal stem cells and uses thereof | Shenzhen Alpha Biopharmaceutical Co. Ltd. (CN) | 2025-06-10 | — | — | US | disclosed |
| CN-119955891-A | Epileptic disease dynamic monitoring method and system based on brain organoids | 同济大学 | 2025-05-09 | — | — | CN | disclosed |
| US-20160024528-A1 | SOMATIC CELL NUCLEAR TRANSFER METHODS | NEW YORK STEM CELL FOUNDATION, INC. | 2016-01-28 | — | — | US | disclosed |
| EP-2971012-A1 | SOMATIC CELL NUCLEAR TRANSFER METHODS | The New York Stem Cell Foundation (US) | 2016-01-20 | — | — | EP | disclosed |
| WO-2015043621-A1 | HAPLOID EMBRYOGENESIS | STICHTING DIENST LANDBOUWKUNDIG ONDERZOEK (NL) | 2015-04-02 | — | — | WO | disclosed |
| WO-2015044199-A1 | HAPLOID EMBRYOGENESIS | STICHTING DIENST LANDBOUWKUNDIG ONDERZOEK (NL) | 2015-04-02 | — | — | WO | disclosed |
| WO-2014144754-A1 | SOMATIC CELL NUCLEAR TRANSFER METHODS | THE NEW YORK STEM CELL FOUNDATION (US) | 2014-09-18 | — | — | WO | disclosed |
| WO-2009117831-A9 | HYBRID MOLECULES HAVING MIXED VITAMIN D RECEPTOR AGONISM AND HISTONE DEACETYLASE INHIBITORY PROPERTIES | THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIVERSITY (CA) | 2009-12-30 | — | — | WO | disclosed |
| WO-2009117831-A1 | HYBRID MOLECULES HAVING MIXED VITAMIN D RECEPTOR AGONISM AND HISTONE DEACETYLASE INHIBITORY PROPERTIES | THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIVERSITY (CA) | 2009-10-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12553028-B2 | Method to generate induced oligodendrocyte-lineage cells and treatment using such cells | HDAC4, HDAC9, MYT1 | HDAC1 9/4885HDAC2 4/4885HDAC6 30/4885 |
| US-20220280656-A1 | COMPOSITIONS AND METHODS FOR TREATING SICKLE CELL DISEASE | HBB, HBG1, HBZ | HDAC1 4862/4885HDAC2 4881/4885HDAC6 4643/4885 |
| US-12496357-B2 | Compositions and methods for treating sickle cell disease | HBB, HBG1, HBZ | HDAC1 4862/4885HDAC2 4881/4885HDAC6 4643/4885 |
| US-20260125650-A1 | METHODS AND COMPOSITIONS FOR GENERATING HEPATOCYTES | WNT3A, GSK3B, GSK3A | HDAC1 71/4885HDAC2 432/4885HDAC6 665/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.